SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Brise Pharmaceuticals Announces Global License Agreement With AbbVie for Migraine Therapies

Brise Pharmaceuticals announced a global license agreement with AbbVie to advance next-generation migraine therapies.

ABBV

Related stories